Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AXN-001
- Development stage
- Phase 1
- Lead developer
- Axonova Pharma
- Modality
- Peptides
- Administration
- Subcutaneous, Intravenous
01
Overview
AXN-001 is a peptide CGRP-R antagonist under development by Axon Therapeutics for the acute treatment of migraine. This investigational drug is designed to block the calcitonin gene-related peptide receptor (CGRP-R), a key target in migraine pathophysiology. It is being evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics, with a subcutaneous formulation intended for self-administration.
02
Targets
Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on AXN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AXN-001.